Global Times: Guangxi’s Zhuang brocade becomes official FIFA World Cup merchandise, showcasing China’s cultural heritage. Beijing, CHINA, May 30, 2026 (GLOBE NEWSWIRE) — Incorporating elements of Guangxi’s Zhuang brocade into official licensed products for this year’s FIFA World Cup, local artisans have recently been busy creating a range of Zhuang brocade-inspired souvenirs, including footballs, jerseys, […]
Category Archives: People
Global Times: Cai Gao, China’s first Hans Christian Andersen Award winner, blends tradition and childhood wonder across 50 years of art. Beijing, CHINA, May 30, 2026 (GLOBE NEWSWIRE) — With silver hair, and a lifetime spent never leaving the world of childhood, 80-year-old Cai Gao, China’s first illustrator to win the Hans Christian Andersen Award, […]
Global Times: Expert Chandran Nair sees China’s 15th Five-Year Plan as a global stability anchor, prioritising rural growth and sustainability. Beijing, CHINA, May 30, 2026 (GLOBE NEWSWIRE) — 2026 marks the commencement of China’s 15th Five-Year Plan (2026-30), a pivotal phase in the nation’s medium to long-term development. A successful venture starts with a good […]
ORION CORPORATION PRESS RELEASE 30 MAY 2026 at 21:30 EEST Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours Data presented at 2026 ASCO® Annual Meeting show ODM-212 was well tolerated, with proteinuria being the most common treatment related adverse event (TRAE) ODM-212 showed early […]
TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening the case for continued development Phase 1/2 trial of EIK1003 reports updated safety and efficacy monotherapy data and initial combination data with weekly […]
First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 expression levels and subtypes, highlighting its potential to set a new standard of care Pumitamig plus chemotherapy showed robust and consistent antitumor activity in first-line non-small cell lung cancer at both evaluated dose levels, with higher confirmed objective response rates at the […]
Exploratory analysis showed favorable patient-reported quality of life outcomes and delayed time to deterioration in patients receiving ¹⁷⁷Lu-edotreotide Data build upon previously reported COMPETE efficacy results, adding patient-centered evidence for ¹⁷⁷Lu-edotreotide in GEP-NETs Chicago, Illinois, May 30, 2026 — ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced encouraging Health-Related Quality […]
– Post hoc analysis from pivotal Launch-HTN trial shows statistically significant and clinically meaningful reductions in blood pressure in participants with chronic kidney disease – – In participants with chronic kidney disease and baseline albuminuria, lorundrostat significantly reduced urine albumin-to-creatinine ratio – – Lorundrostat demonstrated a favorable safety profile in participants with and without chronic […]
Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50, CI: 0.39-0.65, p<0.0001) for bezuclastinib combination compared to sunitinib alone Bezuclastinib combination provides clear PFS benefit regardless of primary or secondary KIT mutations Mean duration of treatment estimated at […]
WOBURN, Mass., May 30, 2026 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented 3-year landmark overall survival data from the IGNYTE clinical trial of RP1 plus nivolumab in patients with anti-PD-1 failed melanoma during an oral session at the 2026 American Society […]


